Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
AI · Healthcare
Boost ROI through pharma-diagnostic collaborations, AI-driven analytics, multi-omics investment, and co-developed companion diagnostics and targeted therapies.
Boost ROI through pharma-diagnostic collaborations, AI-driven analytics, multi-omics investment, and co-developed companion diagnostics and targeted therapies.
Oct 15 · 15:03·GlobeNewswire
Biotech & pharma
Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinoma Exploratory biomarker analysis from the Phase 3 LEAP-001 study adds to translational insights...
Oct 15 · 12:08·PR Newswire
Healthcare · Biotech & pharma
Vancouver, British Columbia--(October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations.In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead candidate, before the...
Oct 15 · 12:00·Newsfile
Healthcare · Biotech & pharma
MADRID and CAMBRIDGE, Mass., Oct. 15, 2026 -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received new decisions to grant for patent applications in South Korea, the Philippines, New Zealand and Mexico, further strengthening its extensive patent portfolio for vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for psychiatric and neurodevelopmental disorders.
Oct 15 · 12:00·GlobeNewswire
Finance · Healthcare
VANCOUVER, British Columbia, Oct. 15, 2026 -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target.
Oct 15 · 12:00·GlobeNewswire
Finance · Healthcare
New Taipei City, Taiwan, Oct. 15, 2026 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative is intended to support the Company’s U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, if approved.
Oct 15 · 12:00·GlobeNewswire
Finance · SaaS
SEATTLE, Oct. 15, 2026 -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
Oct 15 · 12:00·GlobeNewswire
Healthcare · Biotech & pharma
Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism CHICAGO, October 15, 2026 --(
Oct 15 · 12:00·Business Wire
Biotech & pharma
Map ADC opportunities across cancer type, payload, target, product, user and country, with insights on 100 companies, strategic plans, risks and growth drivers.
Map ADC opportunities across cancer type, payload, target, product, user and country, with insights on 100 companies, strategic plans, risks and growth drivers.
Oct 15 · 10:05·GlobeNewswire
AI · SaaS
Collaboration applies insitro's Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical need insitro to receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and commercial milestones, and tiered royalties SOUTH SAN
Oct 15 · 10:00·Business Wire
Healthcare · Biotech & pharma
Available by prescription through telemedicine partner Mavrox.com/Roxus . LTR Pharma Limited (ASX: LTP), the Australian pharmaceutical company, today announced that Roxus® is now available to men across the U.S. Roxus is a prescription nasal spray for erectile dysfunction (ED) that delivers vardenafil, the same type of ED medicine as Viagra®, used in tablets for more than 20 years, through LTR's pro
Oct 15 · 09:18·PR Newswire
AI · SaaS
Springville, UT Thursday Oct 15, 2026 @ 5:00 AM Eastern —
ORGANA, a Utah-based wellness company offering mineral and botanical products, is highlighting an important distinction in its business model: the company manufactures its products in-house, following Good Manufacturing Practices (GMP), rather than relying on third-party contract manufacturers.
While many wellness brands outsource manufacturing to specialized production facilities, ORGANA maintains direct responsibility for its manufacturing operations. This approach gives the company greater oversight of production processes, quality-control procedures and the consistency of its product portfolio.
For ORGANA, in-house manufacturing is part of a broader commitment to maintaining control over how its products are produced, from raw materials through finished goods.
"There's a difference between selling a product with your name on it and actually manufacturing that product yourself," said Larry Mills, CEO of ORGANA. "We've chosen to handle our own manufacturing because we want direct oversight of the products we put into the marketplace. Quality is something we take seriously throughout the process."
ORGANA follows GMP practices in its manufacturing operations, emphasizing established production procedures, quality controls and consistency. By keeping manufacturing in-house, the company can oversee its processes directly rather than depending on outside manufacturers to manage production on its behalf.
The company's manufacturing approach supports a portfolio of mineral and botanical wellness products, including:
Plant-Derived Trace Minerals - A liquid mineral product sourced from an ancient mineral deposit in Utah, offering naturally occurring trace minerals in a convenient format.
Liquid Oxygen 125 PPM - A liquid product that is part of ORGANA's broader wellness portfolio.
Essiac Tea - A botanical product based on a traditional herbal blend.
Pomegranate Mineral Drink - A pomegranate-flavored liquid mineral product offering another way to incorporate minerals into everyday routines.
These products reflect ORGANA's focus on mineral and botanical formulations, with in-house manufacturing providing a consistent approach to production oversight across the portfolio.
Maintaining its own manufacturing operations also allows ORGANA to keep product development and production closely connected. As the company continues to grow its retail presence, this operating model remains an important part of its approach to quality and customer confidence.
"Consumers don't always know who actually makes the products they're buying," Mills added. "For us, manufacturing isn't something we've handed off to another company. It's part of who we are and how we operate."
ORGANA products are available through Amazon, Walmart and OneLavi.com, providing consumers with access to the company's mineral and botanical wellness portfolio.
As ORGANA continues expanding its presence in the U.S. marketplace, the company plans to maintain its focus on in-house manufacturing, GMP practices and direct oversight of production.
About ORGANA International
Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness.
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Oct 15 · 09:00·Newsworthy.ai